HMGB1: The central cytokine for all lymphoid cells

Frontiers in Immunology

Volumn 4, Issue MAR, 2013, Pages

  Li, Guanqiao ^a,b   Liang, Xiaoyan ^a,b   Lotze, Michael T ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

B cells; HMGB1; Lymphocytes; NK cells; RAGE; T cells; TLR2; TLR4

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHEMOKINE RECEPTOR CXCR4; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

AUTOPHAGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; LYMPHOID CELL; NATURAL KILLER CELL; NUCLEOSOME; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 84878346810     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00068     Document Type: Review

References (61)

1. Aderem, A., and Ulevitch, R. (2000). Toll-like receptors in the induction of the innate immune response. Nature 406. Available at: http://gene.bjmu.edu.cn/undereducation_education/download/Toll-like receptor in the induction of the innate immune response.pdf [accessed December 5, 2012].
2. Agrawal, A., and Schatz, D. G. (1997). RAG1 and RAG2 form a stable postcleavage synaptic complex with DNA containing signal ends in V(D)J recombination. Cell 89, 43-53.
3. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059.
4. Avalos, A. M., Kiefer, K., Tian, J., Christensen, S., Shlomchik, M., Coyle, A. J., et al. (2010). RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity 43, 103-110.
5. Bianchi, M. E. (2009). HMGB1 loves company. J. Leukoc. Biol. 86, 573-576.
6. Bonaldi, T., Talamo, F., Scaffidi, P., Ferrera, D., Porto, A., Bachi, A., et al. (2003). Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551-5560.
7. Calogero, S., Grassi, F., Aguzzi, A., Voigtländer, T., Ferrier, P., Ferrari, S., et al. (1999). The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22, 276-280.
8. Chen, G.-Y., Tang, J., Zheng, P., and Liu, Y. (2009). CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323, 1722-1725.
9. Dai, Y., Wong, B., Yen, Y., Oettinger, M. A., Kwon, J., and Johnson, R. C. (2005). Determinants of HMGB proteins required to promote RAG1/2-recombination signal sequence complex assembly and catalysis during V(D)J recombination. Mol. Cell. Biol. 25, 4413-4425.
10. DeMarco, R. A., Fink, M. P., and Lotze, M. T. (2005). Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol. Immunol. 42, 433-444.
11. Duan, L., Wang, C.-Y., Chen, J., Gong, Q., Zhu, P., Zheng, F., et al. (2011). High-mobility group box 1 promotes early acute allograft rejection by enhancing IL-6-dependent Th17 alloreactive response. Lab. Invest. 91, 43-53.
12. Dumitriu, I., and Baruah, P. (2005). Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174, 7506-7515.
13. Dumitriu, I. E., Baruah, P., Bianchi, M. E., Manfredi, A. A., and Rovere-Querini, P. (2005). Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35, 2184-2190.
14. Erlandsson Harris, H., and Andersson, U. (2004). Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur. J. Immunol. 34, 1503-1512.
15. Gardella, S., Andrei, C., Ferrera, D., and Lotti, L. (2002). The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995-1001.
16. George, J., Motshwene, P. G., Wang, H., Kubarenko, A. V., Rautanen, A., Mills, T. C., et al. (2011). Two human MYD88 variants, S34Y and R98C, interfere with MyD88-IRAK4-myddosome assembly. J. Biol. Chem. 286, 1341-1353.
17. Goodwin, G., Rabbani, A., Nicolas, P., and Johns, E. (1977). The isolation of the high mobility group non-histone chromosomal protein HMG14. FEBS Lett. 80, 413-416.
18. Gougeon, M.-L., and Bras, M. (2011). Natural killer cells, dendritic cells, and the alarmin high-mobility group box 1 protein: a dangerous trio in HIV-1 infection? Curr. Opin. HIV AIDS 6, 364-372.
19. He, Y., Zha, J., Wang, Y., Liu, W., Yang, X., and Yu, P. (2012a). Tissue damage-associated "danger signals" influence T cell responses that promote the progression of pre-neoplasia to cancer. Cancer Res. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23108142 [accessed November 17, 2012].
20. He, Z., Shotorbani, S. S., Jiao, Z., Su, Z., Tong, J., Liu, Y., et al. (2012b). HMGB1 promotes the differentiation of Th17 via up-regulating TLR2 and IL-23 of CD14+ monocytes from patients with rheumatoid arthritis. Scand. J. Immunol. 76, 483-490.
21. Ivanov, S., Dragoi, A.-M., Wang, X., Dallacosta, C., Louten, J., Musco, G., et al. (2007). A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110, 1970-1981.
22. Jube, S., Rivera, Z. S., Bianchi, M. E., Powers, A., Wang, E., Pagano, I., et al. (2012). Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 72, 3290-3301.
23. Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H., Yoshimori, T., et al. (2004). The role of autophagy during the early neonatal starvation period. Nature 432, 1032-1036.
24. Lin, S.-C., Lo, Y.-C., and Wu, H. (2010). Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465, 885-890.
25. Liu, Q., Yao, Y., Yan, Y., Dong, N., and Sheng, Z. (2011). High mobility group box 1 protein suppresses T cell-mediated immunity via CD11c(low)CD45RB(high) dendritic cell differentiation. Cytokine 54, 205-211.
26. Lotze, M. T., and Tracey, K. J. (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342.
27. McDonnell, M., Liang, Y., Noronha, A., Coukos, J., Kasper, D. L., Farraye, F. A., et al. (2011). Systemic Toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. Inflamm. Bowel Dis. 17, 298-307.
28. Medzhitov, R. (2001). Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145.
29. Medzhitov, R., and Janeway, C. A. (1997). Innate immunity: the virtues of a nonclonal system of recognition. Cell 91, 295-298.
30. Melki, M.-T., Saïdi, H., Dufour, A., Olivo-Marin, J.-C., and Gougeon, M.-L. (2010). Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk - a pivotal role of HMGB1. PLoS Pathog. 6:e1000862. doi:10.1371/journal.ppat.1000862
31. Messmer, D., Yang, H., Telusma, G., Knoll, F., Li, J., Messmer, B., et al. (2004). High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173, 307-313.
32. Motshwene, P. G., Moncrieffe, M. C., Grossmann, J. G., Kao, C., Ayaluru, M., Sandercock, A. M., et al. (2009). An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J. Biol. Chem. 284, 25404-25411.
33. Müller, S., Scaffidi, P., Degryse, B., Bonaldi, T., Ronfani, L., Agresti, A., et al. (2001). New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20, 4337-4340.
34. Park, J. S., Gamboni-Robertson, F., He, Q., Svetkauskaite, D., Kim, J.-Y., Strassheim, D., et al. (2006). High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290, C917-C924.
35. Park, J. S., Svetkauskaite, D., He, Q., Kim, J.-Y., Strassheim, D., Ishizaka, A., et al. (2004). Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377.
36. Rovere-Querini, P., Capobianco, A., Scaffidi, P., Valentinis, B., Catalanotti, F., Giazzon, M., et al. (2004). HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5, 825-830.
37. Rubartelli, A., and Lotze, M. T. (2007). Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 28, 429-436.
38. Saïdi, H., Melki, M.-T., and Gougeon, M.-L. (2008). HMGB1-dependent triggering of HIV-1 replication and persistence in dendritic cells as a consequence of NK-DC cross-talk. PLoS ONE 3:e3601. doi:10.1371/journal.pone.0003601
39. Scaffidi, P., Misteli, T., and Bianchi, M. E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195.
40. Semino, C., Angelini, G., Poggi, A., and Rubartelli, A. (2005). NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106, 609-616.
41. Semino, C., Ceccarelli, J., Lotti, L. V., Torrisi, M. R., Angelini, G., and Rubartelli, A. (2007). The maturation potential of NK cell clones toward autologous dendritic cells correlates with HMGB1 secretion. J. Leukoc. Biol. 81, 92-99.
42. Shi, Y., Sandoghchian Shotorbani, S., Su, Z., Liu, Y., Tong, J., Zheng, D., et al. (2012). Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin. Dev. Immunol. 2012, 295081.
43. Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., and Coyle, A. J. (2010). HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28, 367-388.
44. Sparvero, L. J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., et al. (2009). RAGE (Receptor for Advanced Glycation End products), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med. 7, 17.
45. Su, Z., Sun, C., Zhou, C., Liu, Y., Zhu, H., Sandoghchian, S., et al. (2011). HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17-cell expansion. Eur. J. Immunol. 41, 3586-3595.
46. Sundberg, E., Fasth, A. E. R., Palmblad, K., Harris, H. E., and Andersson, U. (2009). High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology 214, 303-309.
47. Tang, D., Kang, R., Coyne, C. B., Zeh, H. J., and Lotze, M. T. (2012). PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev. 249, 158-175.
48. Tang, D., Kang, R., Livesey, K. M., Cheh, C.-W., Farkas, A., Loughran, P., et al. (2010a). Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190, 881-892.
49. Tang, D., Kang, R., Zeh, H. J., and Lotze, M. T. (2010b). High-mobility group box 1 and cancer. Biochim. Biophys. Acta 1799, 131-140.
50. Tang, D., and Lotze, M. T. (2012). Tumor immunity times out: TIM-3 and HMGB1. Nat. Immunol. 13, 808-810.
51. Tang, D., Shi, Y., Kang, R., Li, T., Xiao, W., Wang, H., et al. (2007). Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J. Leukoc. Biol. 81, 741-747.
52. Thomas, J. O. (2001). HMG1 and 2: architectural DNA-binding proteins. Biochem. Soc. Trans. 29, 395-401.
53. Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., et al. (2007). Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496.
54. Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D. J., Cattaneo, A., De Marchis, F., et al. (2012). Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209, 1519-1528.
55. Vettermann, C., Castor, D., Mekker, A., Gerrits, B., Karas, M., and Jäck, H.-M. (2011). Proteome profiling suggests a pro-inflammatory role for plasma cells through release of high-mobility group box 1 protein. Proteomics 11, 1228-1237.
56. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., et al. (1999). HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251.
57. Wild, C. A., Bergmann, C., Fritz, G., Schuler, P., Hoffmann, T. K., Lotfi, R., et al. (2012). HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int. Immunol. 24, 485-494.
58. Yanai, H., Ban, T., and Taniguchi, T. (2012). High-mobility group box family of proteins: ligand and sensor for innate immunity. Trends Immunol. 33, 633-640.
59. Yang, D., Chen, Q., Yang, H., Tracey, K. J., Bustin, M., and Oppenheim, J. J. (2007). High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81, 59-66.
60. Zhang, L., Yao, Y., Dong, Y.-Q., Dong, N., Yu, Y., and Sheng, Z. (2008). Relationship between high-mobility group box 1 protein release and T-cell suppression in rats after thermal injury. Shock 30, 449-455.
61. Zhu, X.-M., Yao, Y.-M., Liang, H.-P., Xu, C.-T., Dong, N., Yu, Y., et al. (2011). High mobility group box-1 protein regulate immunosuppression of regulatory T cells through toll-like receptor 4. Cytokine 54, 296-304.